Living donor liver transplantation of the right lobe for hepatocellular carcinoma in cirrhosis in a European center

Sven Jonas, Jens Mittler, Andreas Pascher, Guido Schumacher, Tom Theruvath, Christoph Benckert, Birgit Rudolph, Peter Neuhaus – 30 May 2007 – Living donor liver transplantation of the right lobe might offer the possibility to extend the eligibility criteria of patients with hepatocellular carcinoma (HCC) in cirrhosis without penalizing patients who are waiting for a graft from a deceased donor. From 1988 to 2005, surgical treatment of HCC was performed in 580 patients (187 transplantation, 393 resection) in a European center.

Psychological strain in urgent indications for living donor liver transplantation

Yesim Erim, Mingo Beckmann, Sylvia Kroencke, Camino Valentin‐Gamazo, Massimo Malago, Dieter Broering, Xavier Rogiers, Andrea Frilling, Christoph E. Broelsch, Karl‐Heinz Schulz – 30 May 2007 – The ethical soundness of living donor liver transplantation (LDLT) in urgent indications is still under discussion. The aim of the survey was to investigate the psychological distress of donors in cases of hepatocellular carcinoma (HCC) or acute liver failure (ALF). In a prospective multicenter study (n = 123), health‐related quality of life (QOL), anxiety, and depression were measured.

Posttransplantation lymphoproliferative disorder—The great mimic in liver transplantation: Appraisal of the clinicopathologic spectrum and the role of Epstein‐Barr virus

David G. Koch, Lydia Christiansen, John Lazarchick, Robert Stuart, Ira R. Willner, Adrian Reuben – 30 May 2007 – Case series describing posttransplantation lymphoproliferative disorder (PTLD) after liver transplantation (LTx) have been limited in number because of the rarity of the disorder. The prevalence of Epstein‐Barr virus (EBV) infection and its detection, the clinical and histological diversity of disease, and survival have varied.

Long‐term follow‐up of portopulmonary hypertension: Effect of treatment with epoprostenol

Oren K. Fix, Nathan M. Bass, Teresa De Marco, Raphael B. Merriman – 30 May 2007 – Moderate to severe portopulmonary hypertension (PPHTN) increases the risks of orthotopic liver transplantation (OLT). Epoprostenol is an effective treatment of PPHTN, but long‐term effects on pulmonary hemodynamics or liver function in PPHTN are poorly defined. We sought to describe the long‐term effects of treatment with or without epoprostenol on pulmonary hemodynamics, liver biochemistries, and survival in patients with moderate to severe PPHTN at a single center.

Pharmacokinetics of mycophenolic acid in liver transplant patients after intravenous and oral administration of mycophenolate mofetil

Ashok Jain, Raman Venkataramanan, Tai Kwong, Ravi Mohanka, Mark Orloff, Peter Abt, Randeep Kashyap, Georgios Tsoulfas, Cindy Mack, Mary Williamson, Pam Batzold, Adel Bozorgzadeh – 30 May 2007 – The bioavailability of mycophenolic acid (MPA) after oral administration of mycophenolate mofetil (MMF) has been reported to be more than 90% in healthy volunteers, and in kidney and thoracic organ transplant patients. Such information is limited in liver transplant (LTx) patients.

Subscribe to